The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART).
 
Zakaria Chakrani
No Relationships to Disclose
 
George Slade Mellgard
No Relationships to Disclose
 
Stephen Mccroskery
No Relationships to Disclose
 
Nathaniel Saffran
No Relationships to Disclose
 
Nicole Taylor
No Relationships to Disclose
 
Bobby Chi-Hung Liaw
Consulting or Advisory Role - Bristol Myers Squibb; Bristol Myers Squibb; Daiichi Sankyo; Eisai; EMD Serono; Epizyme; Exelixis; Janssen Biotech; Myovant Sciences
Research Funding - Bayer; Sanofi
 
William K. Oh
Employment - Sema4
Stock and Other Ownership Interests - Sema4
Consulting or Advisory Role - GlaxoSmithKline; Janssen; Merck; Pfizer
 
Kai Tsao
Consulting or Advisory Role - Bristol-Myers Squibb/Sanofi; Eisai; Exelixis
Research Funding - Exelixis; Exelixis
 
Vaibhav G. Patel
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas; Bellicum Pharmaceuticals; crispr therapeutics; Editas Medicine; Finch Therapeutics
Consulting or Advisory Role - Sanofi; Seagen